JP2021065714A - 生理的反応を改善するための方法およびシステム - Google Patents
生理的反応を改善するための方法およびシステム Download PDFInfo
- Publication number
- JP2021065714A JP2021065714A JP2020209161A JP2020209161A JP2021065714A JP 2021065714 A JP2021065714 A JP 2021065714A JP 2020209161 A JP2020209161 A JP 2020209161A JP 2020209161 A JP2020209161 A JP 2020209161A JP 2021065714 A JP2021065714 A JP 2021065714A
- Authority
- JP
- Japan
- Prior art keywords
- immune
- subject
- activity
- cycle
- data
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 73
- 230000006461 physiological response Effects 0.000 title claims description 17
- 238000005070 sampling Methods 0.000 claims abstract description 45
- 238000012545 processing Methods 0.000 claims abstract description 36
- 238000013500 data storage Methods 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims description 216
- 238000012549 training Methods 0.000 claims description 61
- 230000036760 body temperature Effects 0.000 claims description 58
- 238000011084 recovery Methods 0.000 claims description 58
- 238000001356 surgical procedure Methods 0.000 claims description 54
- 210000000987 immune system Anatomy 0.000 claims description 44
- 230000009471 action Effects 0.000 claims description 43
- 239000000090 biomarker Substances 0.000 claims description 43
- 230000036541 health Effects 0.000 claims description 41
- 238000002255 vaccination Methods 0.000 claims description 29
- 230000002747 voluntary effect Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 13
- 239000013589 supplement Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 230000005965 immune activity Effects 0.000 claims description 11
- 230000000284 resting effect Effects 0.000 claims description 8
- 230000037406 food intake Effects 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 238000002483 medication Methods 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 5
- 238000009534 blood test Methods 0.000 claims description 4
- 235000012631 food intake Nutrition 0.000 claims description 4
- 230000036962 time dependent Effects 0.000 claims description 4
- 230000037213 diet Effects 0.000 claims description 3
- 235000018823 dietary intake Nutrition 0.000 claims description 2
- 208000014674 injury Diseases 0.000 description 94
- 230000006378 damage Effects 0.000 description 92
- 208000027418 Wounds and injury Diseases 0.000 description 91
- 239000000306 component Substances 0.000 description 57
- 238000004458 analytical method Methods 0.000 description 30
- 230000004044 response Effects 0.000 description 26
- 238000005259 measurement Methods 0.000 description 25
- 230000028993 immune response Effects 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 16
- 230000035882 stress Effects 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 14
- 230000000770 proinflammatory effect Effects 0.000 description 13
- 238000004891 communication Methods 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 102100032752 C-reactive protein Human genes 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 208000010340 Sleep Deprivation Diseases 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 7
- 238000000554 physical therapy Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 230000009429 distress Effects 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 description 5
- 230000009931 harmful effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000037081 physical activity Effects 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002316 cosmetic surgery Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000010295 mobile communication Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 108700028909 Serum Amyloid A Proteins 0.000 description 3
- 102000054727 Serum Amyloid A Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000024977 response to activity Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 235000019195 vitamin supplement Nutrition 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000011540 hip replacement Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000002169 hydrotherapy Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000013178 mathematical model Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010065433 Ligament rupture Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028331 Muscle rupture Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010072369 Pharyngeal exudate Diseases 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000016334 muscle symptom Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 230000010490 psychological well-being Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009192 sprinting Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B10/0051—Devices for taking samples of body liquids for taking saliva or sputum samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
- A61B5/02055—Simultaneously evaluating both cardiovascular condition and temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4857—Indicating the phase of biorhythm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/486—Bio-feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A63—SPORTS; GAMES; AMUSEMENTS
- A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
- A63B24/00—Electric or electronic controls for exercising apparatus of preceding groups; Controlling or monitoring of exercises, sportive games, training or athletic performances
- A63B24/0075—Means for generating exercise programs or schemes, e.g. computerized virtual trainer, e.g. using expert databases
-
- A—HUMAN NECESSITIES
- A63—SPORTS; GAMES; AMUSEMENTS
- A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
- A63B71/00—Games or sports accessories not covered in groups A63B1/00 - A63B69/00
- A63B71/06—Indicating or scoring devices for games or players, or for other sports activities
- A63B71/0619—Displays, user interfaces and indicating devices, specially adapted for sport equipment, e.g. display mounted on treadmills
- A63B71/0622—Visual, audio or audio-visual systems for entertaining, instructing or motivating the user
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F7/00—Methods or arrangements for processing data by operating upon the order or content of the data handled
- G06F7/06—Arrangements for sorting, selecting, merging, or comparing data on individual record carriers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
- G09B19/0092—Nutrition
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B5/00—Electrically-operated educational appliances
- G09B5/06—Electrically-operated educational appliances with both visual and audible presentation of the material to be studied
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02405—Determining heart rate variability
-
- A—HUMAN NECESSITIES
- A63—SPORTS; GAMES; AMUSEMENTS
- A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
- A63B71/00—Games or sports accessories not covered in groups A63B1/00 - A63B69/00
- A63B71/06—Indicating or scoring devices for games or players, or for other sports activities
- A63B71/0619—Displays, user interfaces and indicating devices, specially adapted for sport equipment, e.g. display mounted on treadmills
- A63B71/0622—Visual, audio or audio-visual systems for entertaining, instructing or motivating the user
- A63B2071/0625—Emitting sound, noise or music
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Primary Health Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Theoretical Computer Science (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Business, Economics & Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Databases & Information Systems (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
Abstract
Description
連続的測定は、主体の免疫状態およびまたは免疫サイクル活動力を決定するために生理的データの2つ以上の測定を行うことを意味する。
105 電子デバイス、デバイス、モバイル通信デバイス
110 電子デバイスデバイス、パーソナルコンピュータ
115 通信ネットワーク、ネットワーク
115 インターネット
120 サーバ、サーバ処理システム
125 データベース試料採取サンプリングデバイス
200 処理システム
202 プロセッサ、処理ユニット
204 メモリ
206 入力デバイス
208 出力デバイス
210 グループ
212 インタフェース
214 記憶デバイス
216 データベース
218 入力データ
220 出力データ
222 通信ポート
400 グラフ
410 日付
415 データポイント、ポイント
425 直線傾向分析
430 最良適合曲線、多項傾向分析
435 期間
440 関数
500 グラフ
505 日付
510 Us-CRP
520 データポイント
530 多項傾向分析、多項分析
535 期間、周期性
540 関数
705 ディスプレイ、スクリーンショット、入力画面
710 スクリーン
805 ディスプレイ、スクリーンショット、入力画面
810 スクリーン
Claims (29)
- 主体における免疫状態または免疫サイクルを決定するためのシステムであって、前記主体は、健康な個体または非慢性的に罹患した個体であり、前記システムは、
2日以上である時間の長さにわたる前記主体の免疫系マーカ、バイオマーカ、および/または体温データに関する免疫系における変化に関連付けられた生理的データを前記主体から取得するための試料採取構成要素と、
前記主体から取得された前記生理的データを記憶するためのデータ記憶構成要素と、
前記時間の長さにわたって捕捉された生理的データを分析し、それによって、それに基づいて前記主体の前記免疫状態または前記免疫サイクルの周期性および前記免疫サイクルを決定し、前記取得された免疫サイクルを外挿し、それによって、将来の免疫状態および/または免疫サイクルを決定する処理構成要素と、
前記主体の前記免疫状態もしくは前記免疫サイクルの周期性、および前記免疫サイクル、ならびに/または前記主体の将来の状態もしくは免疫サイクルを出力するための出力構成要素と
を含むシステム。 - 前記処理構成要素が、主体の前記免疫サイクルおよび/または状態を活動データベースと比較し、前記主体に対する活動に関するスケジューリングまたはタイミングに関する推奨を生成する推論エンジンをさらに含むことを特徴とする、請求項1に記載のシステム。
- 活動に対する主体の生理的反応を改善するためのシステムであって、前記主体は、健康な個体または非慢性的に罹患した個体であり、前記システムは、
前記活動および/または前記主体に関するデータを取得するための入力構成要素と、
2日以上である時間の長さにわたる前記主体の免疫系マーカ、バイオマーカ、および/または体温データに関する免疫系における変化に関連付けられた生理的データを前記主体から取得するための試料採取構成要素と、
前記主体から取得された前記生理的データを記憶するためのデータ記憶構成要素と、
前記時間の長さにわたって捕捉された生理的データを分析し、それによって、それに基づいて前記主体の免疫サイクルの周期性および前記免疫サイクルまたは状態を決定し、前記取得された免疫サイクルを外挿し、それによって、将来の免疫状態および免疫サイクルを決定する処理構成要素と、
前記主体の前記免疫状態、前記免疫サイクルの周期性、前記免疫サイクル、将来の免疫状態、または将来の免疫サイクルについての情報を出力し、前記主体に対する前記活動のデータに基づいて個々の推奨を生成するための出力構成要素と
を含むシステム。 - 前記処理構成要素が、活動データと主体の前記免疫サイクルおよび/または状態を比較し、前記主体に関する活動のスケジューリングまたはタイミングに関する推奨を生成する推論エンジンをさらに含むことを特徴とする、請求項3に記載のシステム。
- 活動が、トレーニングスケジュール、フィットネス体制、ワクチン接種、リハビリテーション、随意の手術または緊急でない手術、食事および食べ物の摂取、補助食品の摂取、薬剤、健やかさおよび健康およびライフスタイルの判断のうちの1つまたは複数を含むことを特徴とする、請求項1または3に記載のシステム。
- 入力構成要素が、前記主体に関する人体計測データおよび生物測定データをさらに取得することを特徴とする、請求項1または3に記載のシステム。
- 前記入力構成要素が、前記活動に関する人体計測データをさらに取得することを特徴とする、請求項3に記載のシステム。
- 前記入力構成要素が、前記主体の栄養摂取、好み、および生活習慣に関するデータをさらに取得することを特徴とする、請求項3に記載のシステム。
- 前記入力構成要素が、推論エンジンが前記活動のタイミング、活動データ、および主体の前記免疫サイクルおよび/または状態を比較し、前記主体に関する推奨を生成するように、活動の日に関連するデータをさらに取得することを特徴とする、請求項3に記載のシステム。
- 前記処理構成要素が、主体の前記免疫サイクルおよび/または状態を比較し、前記主体に関する推奨を生成する推論エンジンをさらに含むことを特徴とする、請求項1または3に記載のシステム。
- 前記生理的データが、免疫系マーカ、または、基礎体温または安静時体温のような前記免疫サイクルおよび/もしくは状態が識別可能なバイオマーカレベルもしくは特性であることを特徴とする、請求項1または3に記載のシステム。
- 前記推奨が、前記活動を実行するスケジュールまたは時間、前記活動を回避すること、前記活動の強度、ある期間にわたって前記活動を延期すること、または前記活動の時間を繰り上げることを含むことを特徴とする、請求項4に記載のシステム。
- 前記推奨が、個体の免疫状態を考慮した前記活動に関連する回復手段のスケジューリングまたはタイミングを含むことを特徴とする、請求項4に記載のシステム。
- 前記免疫サイクルおよび/または状態が、前記生理的データの変動によって決定されることを特徴とする、請求項1または3に記載のシステム。
- 前記生理的データの連続的な時間に依存した変動が、個体の免疫活動力および/または免疫状態を決定する生理的データの少なくとも2つ以上の実例を含むことを特徴とする、請求項1または3に記載のシステム。
- 前記生理的データの連続的な時間に依存した変動は、個体の前記免疫サイクルの前記周期性および/または状態を決定する生理的データの3つ以上の実例を含むことを特徴とする、請求項1または3に記載のシステム。
- 前記試料採取構成要素が、生理的データを測定する1つまたは複数のデバイスを含むことを特徴とする、請求項1または3に記載のシステム。
- 前記試料採取構成要素が、生理的データを手動で受け取る入力デバイスを含むことを特徴とする、請求項1または3に記載のシステム。
- 手動で入力された生理的データが、免疫系マーカ、バイオマーカレベル、または体温のうちの1つまたは複数を含むことを特徴とする、請求項18に記載のシステム。
- 前記1つまたは複数のデバイスが、接触式または非接触式の体温センサ、血液バイオマーカセンサ、血液検査ユニット、または唾液収集ユニットを含むことを特徴とする、請求項17に記載のシステム。
- 請求項1に記載のシステムを用いて主体における免疫状態および/または免疫サイクルを決定するための方法であって、
少なくとも2日である時間の長さにわたる前記主体の免疫系マーカ、バイオマーカ、および/または体温データに関する免疫系における変化に関連付けられた生理的データを前記主体から取得するステップと、
前記時間の長さにわたって捕捉された生理的データを分析し、それによって、前記主体の前記免疫状態および/またはサイクルを決定するステップと、
前記主体の前記免疫状態もしくは前記免疫サイクルの周期性、および前記免疫サイクル、ならびに/または前記主体の将来の状態もしくは将来の免疫サイクルを出力するステップと
を含む方法。 - 主体において活動に対する主体の生理的反応を最適化するための方法であって、前記主体は、健康な個体または非慢性的に罹患した個体であり、前記方法は、
少なくとも2日である時間の長さにわたる前記主体の免疫系マーカ、バイオマーカ、および/または体温データに関する免疫系における変化に関連付けられた活動に関するデータおよび生理的データを前記主体から取得するステップと、
前記時間の長さにわたって捕捉された生理的データを分析し、それに基づいて前記主体の免疫状態または免疫サイクルを決定するステップと、
前記活動および前記主体の免疫サイクルにおける現在または将来の状態に基づいて、1つまたは複数の推奨を行うステップと
を含む方法。 - 免疫状態および/または免疫サイクルが、請求項21に記載の方法によって決定される、請求項22に記載の方法。
- 請求項1から20のいずれか一項に記載のシステムを用いて活動に対する主体の生理的反応を改善するための方法であって、
前記活動に関するデータを取得するステップと、
少なくとも2日である時間の長さにわたる前記主体の免疫系マーカ、バイオマーカ、および/または体温データに関する免疫系における変化に関連付けられた生理的データを前記主体から取得するステップと、
前記生理的データを分析し、それによって、前記主体の免疫サイクルおよび/または状態を決定するステップと、
活動データおよび前記主体の免疫サイクルにおける現在または将来の状態に基づいて、活動のスケジューリングまたはタイミングに関する推奨を行うステップと
を含む方法。 - 前記取得された免疫サイクルを外挿し、それによって、将来の免疫状態および免疫サイクルを決定するステップを含む、請求項21または23に記載の方法。
- 活動データと前記主体の前記免疫サイクルおよび/または状態を比較して、前記生理的データおよび活動データの組合せに基づいて1つまたは複数の推奨を生成するステップ
をさらに含むことを特徴とする、請求項22に記載の方法。 - 前記活動またはアクションプランが、トレーニング、リハビリテーション、随意の手術および緊急でない手術、健やかさおよび健康、ライフスタイルまたはワクチン接種の判断に関連する任意の1つまたは複数であることを特徴とする、請求項24に記載の方法。
- 前記生理的データが、免疫系マーカ、バイオマーカ、および/または体温のうちの1つまたは複数を含むことを特徴とする、請求項24に記載の方法。
- 主体において免疫状態もしくは免疫サイクルを決定する、または活動に対する主体の生理的反応を改善するための方法であって、請求項1から20のいずれか一項に記載のシステムの使用を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014904929A AU2014904929A0 (en) | 2014-12-05 | Method and system for improving a physiological response | |
AU2014904929 | 2014-12-05 | ||
JP2017548501A JP2018507416A (ja) | 2014-12-05 | 2015-12-03 | 生理的反応を改善するための方法およびシステム |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017548501A Division JP2018507416A (ja) | 2014-12-05 | 2015-12-03 | 生理的反応を改善するための方法およびシステム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021065714A true JP2021065714A (ja) | 2021-04-30 |
JP7328200B2 JP7328200B2 (ja) | 2023-08-16 |
Family
ID=56090737
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017548501A Pending JP2018507416A (ja) | 2014-12-05 | 2015-12-03 | 生理的反応を改善するための方法およびシステム |
JP2020209161A Active JP7328200B2 (ja) | 2014-12-05 | 2020-12-17 | 生理的反応を改善するための方法およびシステム |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017548501A Pending JP2018507416A (ja) | 2014-12-05 | 2015-12-03 | 生理的反応を改善するための方法およびシステム |
Country Status (13)
Country | Link |
---|---|
US (1) | US20170360356A1 (ja) |
EP (1) | EP3226750A4 (ja) |
JP (2) | JP2018507416A (ja) |
KR (1) | KR102543793B1 (ja) |
CN (2) | CN107205645A (ja) |
AU (1) | AU2015358294B2 (ja) |
BR (1) | BR112017011557A2 (ja) |
CA (1) | CA2969133A1 (ja) |
IL (1) | IL252690B (ja) |
MX (1) | MX2017007142A (ja) |
NZ (1) | NZ732891A (ja) |
RU (1) | RU2719954C2 (ja) |
WO (1) | WO2016086271A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10835782B2 (en) * | 2016-06-01 | 2020-11-17 | Samsung Electronics Co., Ltd. | Electronic device, system, and method for determining suitable workout in consideration of context |
US11039763B2 (en) * | 2017-01-13 | 2021-06-22 | Hill-Rom Services, Inc. | Interactive physical therapy |
NL2018435B1 (en) * | 2017-02-27 | 2018-09-19 | Univ Amsterdam | Assembly, method and computer program product for influencing a biological process |
EP3542859A1 (en) | 2018-03-20 | 2019-09-25 | Koninklijke Philips N.V. | Determining a medical imaging schedule |
CN108922620A (zh) * | 2018-06-20 | 2018-11-30 | 南华大学 | 一种手术切口感染风险评估*** |
CN110639191A (zh) * | 2018-06-27 | 2020-01-03 | 北京东方兴企食品工业技术有限公司 | 用于评估机体运动能力的***及其应用 |
WO2021097653A1 (en) * | 2019-11-19 | 2021-05-27 | National University Of Singapore | Optimisation of combination drug therapies |
US20220061745A1 (en) * | 2020-09-03 | 2022-03-03 | Jose Baldera | System and process for immune system evaluation |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007509078A (ja) * | 2003-10-24 | 2007-04-12 | イミュネイド ピーティーワイ リミテッド | 治療の方法 |
JP2008512654A (ja) * | 2004-09-08 | 2008-04-24 | イミューンネイド ピーティーワイ リミテッド | 自己免疫疾患および変性疾患を治療する方法 |
KR20090003748A (ko) * | 2007-07-03 | 2009-01-12 | 서울대학교산학협력단 | 환자 맞춤형 건강관리 시스템 및 그 방법 |
JP2011511297A (ja) * | 2008-02-08 | 2011-04-07 | ファディア・アクチボラグ | 臨床判断サポートを可能にする方法、コンピュータプログラム製品およびシステム |
US20120303284A1 (en) * | 2009-12-17 | 2012-11-29 | Mayo Foundation For Medical Education And Research | Determination of timing of chemotherapy delivery |
US20130151165A1 (en) * | 2009-05-27 | 2013-06-13 | Immunaid Pty Ltd. | Computer Systems for Treating Diseases |
US20140310019A1 (en) * | 2010-07-27 | 2014-10-16 | Segterra Inc. | Methods and Systems for Generation of Personalized Health Plans |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8234129B2 (en) * | 2005-10-18 | 2012-07-31 | Wellstat Vaccines, Llc | Systems and methods for obtaining, storing, processing and utilizing immunologic and other information of individuals and populations |
WO2007051258A1 (en) * | 2005-11-04 | 2007-05-10 | Resmed Ltd | Blood protein markers in methods and apparatuses to aid diagnosis and management of sleep disordered breathing |
CA2651458A1 (en) * | 2006-05-05 | 2007-11-15 | Mevitec Gmbh | Device and method for examination and evaluation of a biological active and/or biological activatable substance |
RU2371727C2 (ru) * | 2007-03-29 | 2009-10-27 | ГУ Научно-исследовательский институт эпидемиологии и микробиологии Сибирского отделения Российской академии медицинских наук (ГУ НИИЭМ СО РАМН) | Способ оценки состояния иммунитета |
EP2218022A4 (en) * | 2007-11-08 | 2011-03-09 | Wellstat Vaccines Llc | AUTOMATED SYSTEMS AND METHODS FOR OBTAINING, STORING, PROCESSING AND USING IMMUNOLOGICAL AND OTHER INDIVIDUAL AND POPULATION INFORMATION FOR VARIOUS USES |
CA2778270C (en) * | 2009-10-19 | 2021-01-05 | Theranos, Inc. | Integrated health data capture and analysis system |
-
2015
- 2015-12-03 CN CN201580066824.1A patent/CN107205645A/zh active Pending
- 2015-12-03 KR KR1020177018508A patent/KR102543793B1/ko active IP Right Grant
- 2015-12-03 CN CN202311776269.4A patent/CN117789914A/zh active Pending
- 2015-12-03 NZ NZ732891A patent/NZ732891A/en unknown
- 2015-12-03 BR BR112017011557A patent/BR112017011557A2/pt not_active Application Discontinuation
- 2015-12-03 MX MX2017007142A patent/MX2017007142A/es unknown
- 2015-12-03 WO PCT/AU2015/050762 patent/WO2016086271A1/en active Application Filing
- 2015-12-03 AU AU2015358294A patent/AU2015358294B2/en active Active
- 2015-12-03 US US15/533,365 patent/US20170360356A1/en active Pending
- 2015-12-03 RU RU2017123538A patent/RU2719954C2/ru active
- 2015-12-03 EP EP15864947.5A patent/EP3226750A4/en active Pending
- 2015-12-03 CA CA2969133A patent/CA2969133A1/en active Pending
- 2015-12-03 JP JP2017548501A patent/JP2018507416A/ja active Pending
-
2017
- 2017-06-05 IL IL252690A patent/IL252690B/en active IP Right Grant
-
2020
- 2020-12-17 JP JP2020209161A patent/JP7328200B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007509078A (ja) * | 2003-10-24 | 2007-04-12 | イミュネイド ピーティーワイ リミテッド | 治療の方法 |
JP2008512654A (ja) * | 2004-09-08 | 2008-04-24 | イミューンネイド ピーティーワイ リミテッド | 自己免疫疾患および変性疾患を治療する方法 |
KR20090003748A (ko) * | 2007-07-03 | 2009-01-12 | 서울대학교산학협력단 | 환자 맞춤형 건강관리 시스템 및 그 방법 |
JP2011511297A (ja) * | 2008-02-08 | 2011-04-07 | ファディア・アクチボラグ | 臨床判断サポートを可能にする方法、コンピュータプログラム製品およびシステム |
US20130151165A1 (en) * | 2009-05-27 | 2013-06-13 | Immunaid Pty Ltd. | Computer Systems for Treating Diseases |
US20120303284A1 (en) * | 2009-12-17 | 2012-11-29 | Mayo Foundation For Medical Education And Research | Determination of timing of chemotherapy delivery |
US20140310019A1 (en) * | 2010-07-27 | 2014-10-16 | Segterra Inc. | Methods and Systems for Generation of Personalized Health Plans |
Also Published As
Publication number | Publication date |
---|---|
JP2018507416A (ja) | 2018-03-15 |
RU2719954C2 (ru) | 2020-04-23 |
EP3226750A1 (en) | 2017-10-11 |
WO2016086271A1 (en) | 2016-06-09 |
JP7328200B2 (ja) | 2023-08-16 |
US20170360356A1 (en) | 2017-12-21 |
RU2017123538A (ru) | 2019-01-09 |
CN117789914A (zh) | 2024-03-29 |
EP3226750A4 (en) | 2018-07-04 |
NZ732891A (en) | 2022-09-30 |
RU2017123538A3 (ja) | 2019-05-31 |
CN107205645A (zh) | 2017-09-26 |
AU2015358294A1 (en) | 2017-07-06 |
IL252690A0 (en) | 2017-08-31 |
IL252690B (en) | 2021-01-31 |
CA2969133A1 (en) | 2016-06-09 |
BR112017011557A2 (pt) | 2018-03-06 |
MX2017007142A (es) | 2017-10-11 |
KR20170116012A (ko) | 2017-10-18 |
AU2015358294B2 (en) | 2021-06-24 |
KR102543793B1 (ko) | 2023-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7328200B2 (ja) | 生理的反応を改善するための方法およびシステム | |
US20230240596A1 (en) | Method and apparatus for the measurement of autonomic function for the diagnosis and validation of patient treatments and outcomes | |
WO2017166074A1 (zh) | 一种数据处理的方法及装置 | |
US20140316220A1 (en) | Personal Health Monitoring System | |
Hornbuckle et al. | Effects of high-intensity interval training on cardiometabolic risk in overweight and obese African-American women: a pilot study | |
US11589788B2 (en) | Prediction of mood and associated outcomes based on correlation of autonomous and endocrine parameters | |
US20180110462A1 (en) | Device, system and method for detecting illness- and/or therapy-related fatigue of a person | |
US20140324443A1 (en) | Health Scoring Systems and Methods | |
Langelotz et al. | Stress and heart rate variability in surgeons during a 24-hour shift | |
Herbell et al. | Reducing psychological stress in peripartum women with heart rate variability biofeedback: a systematic review | |
Ramsey et al. | Physical activity intensity of patient’s with traumatic brain injury during inpatient rehabilitation | |
US20180203009A1 (en) | Device, system and method for managing treatment of an inflammatory autoimmune disease of a person | |
Dunn et al. | Cardiovascular reactivity to stressors: effect of time of day? | |
US20220110584A1 (en) | Dosage regimen supporting apparatus and dosage regimen supporting system | |
Jones et al. | Within-subject correlations between evening-related changes in body temperature and melatonin in the spinal cord injured | |
US20200161001A1 (en) | Personal Data Analytics System | |
Zayachkivska et al. | Detection of early risk factors of stress in students using SMART LION m-Health technologye | |
WO2022163826A1 (ja) | 健康支援装置、健康支援システム、健康支援方法 | |
US20230210443A1 (en) | Device for correlating a biometric variation with an external stimulus and related methods and systems | |
KR20230041555A (ko) | 월경장애를 예측하고 관리하기 위한 방법 및 디지털 치료제 | |
Moore et al. | US Health care technologies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210114 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230313 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230613 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230710 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230803 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7328200 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |